LifeArc backs trials to re-purpose drugs for COVID-19 therapies

Graphic image of two heads communicating with thought and text bubbles to show LifeArc backs trials into re-purposed therapies for COVID-19

Medical research charity, LifeArc is providing £10m for clinical trials to find effective COVID-19 therapies. All 15 projects – involving nearly 30 different organisations – were selected for their ability to rapidly start trials in patients and the likelihood of success.

The trials involve medicines that are approved for use in other indications or those in late-stage development with known mechanism of action. This re-purposing approach, where the drug is known to have a target that could be relevant to COVID-19 patients, has a high chance of identifying a treatment in a shorter time than it would take to develop either vaccines or new medicines

Dr Catriona Crombie, Associate Director Technology Transfer, LifeArc, said of the announcement that LifeArc was providing £10m for clinical trials to find effective COVID-19 therapies: “The quality and quantity of submissions in such a short time frame demonstrated the need for the rapid availability of funding. We are delighted that, as an independently funded charity, LifeArc could respond rapidly and use our resources to identify and support those research projects that had the highest potential to be made available to patients as soon as possible.”

In response to our call to scientists and researchers to submit promising approaches to re-purpose medicines to address COVID-19, LifeArc received more than 130 submissions from organisations across the globe. The charity drew up a short-list of applications using criteria that included the scientific rationale of the approach and ability to start trials within 6 to 12 months.

An independent, expert Scientific Review Panel assessed the shortlisted applicants and those with the highest chance of delivering an improvement to COVID-19 patients were selected for funding.

Organisations involved in the studies come from around the globe, including the UK, China, North America and Japan. The principal investigators are primarily universities, research centres or hospitals.

Professor Stephen Holgate, Chair of the Scientific Review Panel and Professor of Immunopharmacology, University of Southampton, said: “Finding new treatments for COVID-19 is a hugely important task and this is an important initiative to happen at this crucial time. Responses to this call include so many imaginative and exciting proposals. The panel members did a wonderful job evaluating the applications and I am most grateful to them for the time and effort each of them put into the assessments.”

The submissions covered a range of approaches from new antivirals, immune modulators and anti-thrombotics to treat patients at different stages of infection including prophylaxis, right through to those requiring ventilation.

A number of academic and medical researchers will be collaborating with biotechnology and pharmaceutical companies on the trials. Additional charity and state funders are also providing support.

The LifeArc funding contributes to the national and international response from across the life sciences sector.

Of the 15 proposals selected by the panel, seven have contracts finalised and the details are provided below. The remaining eight will be subject to a further announcement.

More information on the investment into COVID-19 therapies can be found on the LifeArc website and details of the studies are in the table below.


Keep up to date with COVID-19 news and features for pharma and healthcare


Study Name Principal investigating facilityProject title
Almitrine bismesylate in Covid-19University of OxfordTo determine whether administration of almitrine bismesylate can ameliorate hypoxaemia in COVID-19 and augment effectiveness of supplementary oxygen therapy and respiratory support.
ATTRACTUniversity College LondonA randomized phase 2 placebo-controlled clinical study named ATTRACT (Angiotensin II Type Two Receptor Agonist Covid-19 Trial) to test the impact of an AT2R agonist (VP01) on progression of COVID-19 disease.
DEFEAT-COVID studyAshford and St Peters Hospital NHS Trust, Guangdong Uni-Innovation Pharmaceuticals Co., LtdTargeting de novo Pyrimidine Biosynthesis by leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19).
FLARE TrialUniversity College LondonFavipiravir, lopinavir/ritonavir or combination therapy: a randomised, double blind, 2×2 factorial placebo-controlled trial of early antiviral therapy in COVID-19 (the FLARE trial).
PIONEER TrialChelsea and Westminster Hospital NHS Foundation Trust, Royal Brompton Hospital, Imperial CollegeA randomised controlled trial investigating antiviral drug favipiravir as interventional treatment for hospitalized COVID-19 patients.
RAVENKing’s College LondonRuxolitinib therapy to Avoid Ventilation and improve outcome for deteriorating COVID-19 patiENts.
SPIKE-1 TrialThe University of EdinburghA randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.